IP Library Granted Patent US 8,435,553
Granted Patent B2
US 8,435,553 · App. 13/333,592 · Granted May 7, 2013

Elastin stabilization of connective tissue

Inventors: Narendra R. Vyavahare (Easley, SC); Jason C. Isenburg (Pendleton, SC); Dan T. Simionescu (Central, SC)
Assignee: Clemson University Research Foundation (CURF)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,435,553
App. No.
13/333,592
Granted
May 7, 2013
Kind
B2
Abstract

A method and product are provided for the treatment of connective tissue weakened due to destruction of tissue architecture, and in particular due to elastin degradation. The treatment agents employ certain unique properties of phenolic compounds to develop a protocol for reducing elastin degradation, such as that occurring during aneurysm formation in vasculature. According to the invention, elastin can be stabilized in vivo and destruction of connective tissue, such as that leading to life-threatening aneurysms in vasculature, can be tempered or halted all together. The treatment agents can be delivered or administered acutely or chronically according to various delivery methods, including sustained release methods incorporating perivascular or endovascular patches, use of microsphere carriers, hydrogels, or osmotic pumps.

Claims (24)

1. An implantable element for stabilization of blood vessel in a living subject, comprising a structural element selected from a group consisting of a vascular graft, a stent graft, and a stent and a therapeutic composition associated with the structural element,

wherein the therapeutic composition comprises a phenolic compound having a plurality of phenolic groups at an effective concentration that crosslinks elastin in the blood vessel in vivo to stabilize the blood vessel, and

wherein the therapeutic composition is substantially free of unbound gallic acid and has a pH between about 4 and about 9.

2. The implantable element of claim 1 wherein the structural element is a stent graft that is configured to reinforce a section of blood vessel that has aneurysm without removal of the section of the blood vessel.

3. The implantable element of claim 1 wherein the structural element is a vascular graft comprising a tubular element that forms a suitable replacement for a section of blood vessel that has aneurysm.

4. The implantable element of claim 1 wherein the structural element comprises a bio-absorbable material.

5. The implantable element of claim 1 wherein the therapeutic composition is associated with the structural element in the form of a coating.

6. The implantable element of claim 1 wherein the therapeutic composition is embedded in the structural element.

7. The implantable element of claim 1 wherein the phenolic compound is tannic acid or an analog of tannic acid, pentagalloylglucose or an analog of pentagalloylglucose, a combination thereof, or a pharmaceutically acceptable salt thereof.

8. The implantable element of claim 1 wherein the therapeutic composition comprises from about 0.0001 w/v % to about 10 w/v % of the phenolic compound.

9. The implantable element of claim 1 wherein the therapeutic composition further comprises glutaraldehyde.

10. The implantable element of claim 1 wherein the therapeutic composition further comprises a drug delivery vehicle comprising a sustained release drug delivery vehicle.

11. The implantable element of claim 1 wherein the therapeutic composition further comprises a drug delivery vehicle comprising a hydrogel.

12. The implantable element of claim 10 wherein the therapeutic composition is encapsulated in the drug delivery vehicle.

13. A method for stabilization of blood vessel of a living subject using an implantable element that comprises a structural element selected from a group consisting of a vascular graft, a stent graft, and a stent and a therapeutic composition associated with the structural element, wherein the therapeutic composition comprises a phenolic compound having a plurality of phenolic groups at an effective concentration that crosslinks elastin in the blood vessel in vivo to stabilize the blood vessel, the method comprising,

implanting the implantable element in the blood vessel, and

allowing the therapeutic composition to elute from the implantable element to stabilize the blood vessel.

14. The method of claim 13 wherein the phenolic compound is tannic acid or an analog of tannic acid, pentagalloylglucose or an analog of pentagalloylglucose, a combination thereof, or a pharmaceutically acceptable salt thereof.

15. The method of claim 13 wherein the implanting step comprises replacing a section of blood vessel that has aneurysm with the vascular graft.

16. The method of claim 13 wherein the implanting step comprises deployment of the stent at an aneurysm.

17. The method of claim 16 wherein the stent stabilizes the blood vessel that has the aneurysm.

18. The method of claim 13 wherein the implanting step comprises reinforcing a section of blood vessel that has aneurysm with the stent graft without removal of the section of the blood vessel.

19. The method of claim 13 wherein the therapeutic composition further comprises a drug delivery vehicle comprising a sustained release drug delivery vehicle to allow sustained elution of the therapeutic composition from the structural element.

20. The method of claim 13 further comprising treating the blood vessel with glutaraldehyde before, during, or after the implantation of the implantable element.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 13, 2026
From: DARDI & HERBERT, PLLC
To: NECTERO MEDICAL, INC.
Reel/Frame 074069/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2018
From: VYAVAHARE, NARENDRA R.; ISENBURG, JASON; SIMIONESCU, DAN T.
To: CLEMSON UNIVERSITY
Reel/Frame 046505/0179 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2018
From: CLEMSON UNIVERSITY
To: CLEMSON UNIVERSITY RESEARCH FOUNDATION (CURF)
Reel/Frame 046505/0286 →
SECURITY INTEREST Recorded Apr 13, 2017
From: VATRIX MEDICAL, INC.
To: DARDI & HERBERT, PLLC
Reel/Frame 042000/0962 →
CONFIRMATORY LICENSE Recorded Feb 8, 2013
From: CLEMSON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029777/0992 →
Continuity (5)
Division 12748849 · Mar 29, 2010
Continuation 11827121 · Jul 10, 2007
Continuation 11387454 · Mar 23, 2006
Provisional Application 60674631 · Apr 25, 2005
Related Publication 20120114732A1 · May 10, 2012